The 2nd ISCC

October 15, 1997
Nagai Memorial Hall

Program

9:00-09:05

Haruo Sugano (Cancer Chemotherapy Center)

Welcome and Introduction

I. Future Directions for Drug Development by the NCI

Chairperson: Haruo Sugano (Cancer Chemotherapy Center)

9:05-9:35

Edward A. Sausville (NCI)

9:35-9:40

Discussion

9:40-9:55

Coffee Break

II-I. New Insights in Antimetabolites (Part I)

Chairpersons: Mace L. Rothenberg (Univ. Texas)
Yutaka Ariyoshi (Aichi Hospital)

1. TS Inhibitors

09:55-10:20

Carmen J. Allegra (NCI)

Preclinical and clinical investigations of MTA

10:20-10:45

Mark P. Smith (Zeneca Pharmaceuticals, UK)

Raltitrexed (TomudexTM) combinations: Phase I trials

10:45-11:00

Keisuke Aiba (Cancer Chemotherapy Center)

Clinical trials with raltitrexed in Japan

11:00-11:15

Discussion

2. Gemcitabine

11:15-11:30

Masahiro Fukuoka (Kinki Univ.)

Gemcitabine in non-small cell lung cancer

11:30-11:55

Mace L. Rothenberg (Univ. Texas)

Current status of gemcitabine in the United States

11:55-12:10

Discussion

12:10-13:10

Lunch Break

II-II. New Insights in Antimetabolites (Part II)

Chairpersons: Edward A. Sausville (NCI)
Noboru Horikoshi (Cancer Chemotherapy Center)

3. Modified Cytosine Nucleosides Developed in Japan

Akira Matsuda (Hokkaido Univ.)

Chemical overview of modified cytosine nucleosides

13:25-13:35

Masanori Miwa (Nippon Roche Research Center)

Positive correlation between antitumor activity of 2'-deoxy-2'-methylidenecytidine (DMDC) and cytidine deaminase activity in tumors and its possible mechanism

13:35-13:45

Junji Kanazawa (Kyowa Hakko Kogyo Co.)

Mechanism of antitumor activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine (FMDC), a new 2'-deoxycytidine antimetabolite

13:45-13:55

Tomowo Kobayashi (Sankyo Co.)

Antitumor activity of a novel nucleoside l-(2-C-cyano-2-deoxy-b-D-arabino-pentofuranosyl)-N4-palmitoylcytosine (CS-682)

13:55-14:05

Yuji Shimamoto (Taiho Pharmaceutical Co.)

Novel antitumor ribonucleoside, 3'-ethynylcytidine: antitumor activity and pharmacology

14:05-14:20

Discussion

14:20-14:35

Coffee Break

III. New Antitumor Agents : Basic and Clinical Aspects

Chairpersons: Bruce A. Chabner (MGH Cancer Center)
Takashi Tsuruo (Univ. Tokyo)

1.Cryptophan

14:35-15:00

Frederick A. Valeriote (Wayne State Univ.)

2. Flavopiridol

15:00-15:25

Edward A. Sausville (NCI)

Preclinical and clinical studies with flavopiridol

3. Thrombopoietin

15:25-15:50

David J. Kuter (MGH Cancer Center)

Thrombopoietin : biology and applications in oncology

4. TOP-53

15:50-16:05

Takashi Kobunai (Taiho Pharmaceutical Co.)

Preclinical-pharmacology and early clinical development of TOP-53, a novel podophyllotoxin derivative

5. CGP57148

16:05-16:20

Shingo Dan (Univ. Tokyo)

Selective induction of apoptosis in Philadelphia chromosome-positive K562 cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148

6. E7070

16:20-16:35

Kentaro Yoshimatsu (Eisai Co.)

E7070: a novel sulfonamide antitumor agent, targeting Gl phase

16:35-16:55

Coffee Break

IV. Development of New Antitumor Agents in Europe and Japan: Present Situation and Future Perspectives

Chairpersons: Yasuhiro Shimada (National Cancer Center Hospital)
Yasutsuna Sasaki (National Cancer Center Hospital East)

16:55-17:15

Coenraad van Kalken (EORTC-New Drug Development Office, Netherlands)

New anticancer drug development in Europe; the approach of the European Organization for Research and Treatment of Cancer (EORTC)

17:15-17:35

Nagahiro Saijo (National Cancer Center Research Inst.)

Development of new antitumor agents in Europe and Japan: present situation and future perspectives

17:35-17:50

Discussion

V. Chemotherapy and the Elderly: What We Know and What We Think We Know

Chairperson: Makoto Ogawa (Aichi Cancer Center)

17:50-18:20

Bruce A. Chabner (MGH Cancer Center)

18:20-18:25

Discussion

Closing Remark

18:25-18:30

Takashi Tsuruo (Univ. Tokyo)

18:30-19:30

Mixer

Page TOP